BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 09-Nov-2020

(Cont. of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 2.84, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 76.77, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 68.69 and Consolidated NOCFPS of Tk. 8.04 for the year ended on June 30, 2020 as against Tk. 3.77, Tk. 75.19, Tk. 66.98 and Tk. 6.19 respectively for the same period of the previous year. (end)

ORIONPHARM 31-May-2020

(Q3 Un-audited): Consolidated EPS was Tk. 0.61 for January-March 2020 as against Tk. 0.95 for January-March 2019; Consolidated EPS was Tk. 2.75 for July'19-March'20 as against Tk. 3.01 for July'18-March'19. Consolidated NOCFPS was Tk. 2.73 for July'19-March'20 as against Tk. 7.15 for July'18-March'19. (cont.)

ORIONPHARM 28-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 0.97 for October-December 2019 as against Tk. 1.08 for October-December 2018; Consolidated EPS was Tk. 2.14 for July-December 2019 as against Tk. 2.06 for July-December 2018. Consolidated NOCFPS was Tk. 3.11 for July-December 2019 as against Tk. 4.98 for July-December 2018. (cont.)

ORIONPHARM 13-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 1.17 for July-September 2019 as against Tk. 0.98 for July-September 2018; Consolidated NOCFPS was Tk. 1.96 for July-September 2019 as against Tk. 2.62 for July-September 2018. Consolidated NAV per share (including revaluation surplus) was Tk. 76.33 as on September 30, 2019 and Tk. 75.19 as on June 30, 2019. Consolidated NAV per share (excluding revaluation surplus) was Tk. 68.15 as on September 30, 2019 and Tk. 66.98 as on June 30, 2019.

ORIONPHARM 07-Nov-2019

(Continuation news of ORIONPHARM): The Company has also reported Consolidated EPS of Tk. 3.77, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 75.19, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 66.98 and Consolidated NOCFPS of Tk. 6.19 for the year ended on June 30, 2019 as against Tk. 3.43, Tk. 72.88, Tk. 64.55 and Tk. 9.38 respectively for the same period of the previous year. (cont.2)

ORIONPHARM 02-May-2019

(Q3 Un-audited): Consolidated EPS was Tk. 0.95 for January-March 2019 as against Tk. 0.69 for January-March 2018; Consolidated EPS was Tk. 3.01 for July'18-March'19 as against Tk. 2.76 for July'17-March'18. Consolidated NOCFPS was Tk. 7.15 for July'18-March'19 as against Tk. 8.57 for July'17-March'18. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 74.29 and Tk. 66.05 respectively as on March 31, 2019 as against Tk. 72.88 and Tk. 64.55 respectively as on June 30, 2018.

ORIONPHARM 03-Feb-2019

(Q2 Un-audited): Consolidated EPS was Tk. 1.08 for October-December, 2018 as against Tk. 0.97 for October-December, 2017; Consolidated EPS was Tk. 2.06 for July-December, 2018 as against Tk. 2.07 for July-December, 2017. Consolidated NOCFPS was Tk. 4.98 for July-December, 2018 as against Tk. 4.81 for July-December, 2017. (cont.)

ORIONPHARM 15-Nov-2018

(Q1 Un-audited): Consolidated EPS was Tk. 0.98 for July-September, 2018 as against Tk. 1.10 for July-September, 2017; Consolidated NOCFPS was Tk. 2.62 for July-September, 2018 as against Tk. 2.53 for July-September, 2017. Consolidated NAV per share (including revaluation surplus) was Tk. 73.65 as on September 30, 2018 and Tk. 72.05 as on September 30, 2017. Consolidated NAV per share (excluding revaluation surplus) was Tk. 65.35 as on September 30, 2018 and Tk. 63.62 as on September 30, 2017.

ORIONPHARM 01-Nov-2018

The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2018. Date of AGM: 10.12.2018, Time: 11:00 AM, Venue: Officer's Club, 26, Baily Road, Ramna, Dhaka. Record Date: 22.11.2018. The Company has also reported Consolidated EPS of Tk. 3.43, Consolidated NAV per share (including Revaluation Surplus) of Tk. 72.88 and Consolidated NOCFPS of Tk. 9.38 for the year ended on June 30, 2018 as against Tk. 3.40, Tk. 70.95 and Tk. 9.62 respectively for the year ended on June 30, 2017.

ORIONPHARM 30-Apr-2018

(Q3 Un-audited): Consolidated EPS was Tk. 0.69 for January-March 2018 as against Tk. 0.56 for Jan.-Mar. 2017; Consolidated EPS was Tk. 2.76 for July'17-March'18 as against Tk. 3.02 for July'16-March'17. Consolidated NOCFPS was Tk. 8.57 for July'17-March'18 as against Tk. 8.54 for July'16-March'17. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 72.07 and Tk. 63.71 respectively as on March 31, 2018 as against Tk. 70.95 and Tk. 62.48 respectively as on June 30, 2017.

Previous Next page